Shang Yu-Xi, Wang Li-Ru
Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China.
Department of Hematology, Fuxing Hospital, Capital Medical University, Beijing 100038, China. E-mail:
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2016 Feb;24(1):241-4. doi: 10.7534/j.issn.1009-2137.2016.01.046.
Malignant hematologic disease with sepsis has been characterized by high mortality and difficulty in diagnosis at early stage. A good biomarker may help to improve the accuracy of diagnosis and to reduce the mortality rate. In the early diagnosis of sepsis, neutrophil CD64 expression is a better candidate for biomarker rather than C-reactive proteins. Moreover, neutrophil CD64 expression is also helpful for assessing the severity of infection and prognosis of disease. Unfortunately, there are few studies of neutrophil CD64 expression on the early diagnosis of malignant hematologic diseases. This review focuses on the advantages, limitations, feasibilities and progresses of neutrophil CD64 expression in the early diagnosis of infection in malignant hematologic diseases in this paper.
伴有脓毒症的恶性血液病具有高死亡率和早期诊断困难的特点。一种良好的生物标志物可能有助于提高诊断准确性并降低死亡率。在脓毒症的早期诊断中，中性粒细胞CD64表达比C反应蛋白更适合作为生物标志物。此外，中性粒细胞CD64表达也有助于评估感染的严重程度和疾病的预后。遗憾的是，关于中性粒细胞CD64表达在恶性血液病早期诊断方面的研究较少。本文综述了中性粒细胞CD64表达在恶性血液病感染早期诊断中的优势、局限性、可行性及进展。
